THERAVANCE INC's gross profit margin for the first quarter of its fiscal year 2015 has significantly decreased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. THERAVANCE INC is extremely liquid. Currently, the Quick Ratio is 23.81 which clearly shows the ability to cover any short-term cash needs. THRX managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 198.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||6.9||-0.78|
|Net Income ($mil)||-10.67||-67.7|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||251.14||370.92|
|Total Assets ($mil)||488.7||605.03|
|Total Debt ($mil)||732.06||287.5|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||11.19||1887.56|
|Return on Assets||-22.8||-33.22|
|Return on Equity||0.0||-13.7|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||116.77||112.52|
|Div / share||0.25||0.0|
|Book value / share||-2.23||2.34|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||589103.0||922600.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium.
|THRX NM||Peers 33.24||THRX NM||Peers 24.85|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
THRX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
THRX's P/CF is negative making the measure meaningless.
|THRX 34.33||Peers 18.88||THRX NA||Peers 1.00|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
THRX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|THRX NM||Peers 11.85||THRX -76.47||Peers 21.38|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
THRX's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, THRX is expected to significantly trail its peers on the basis of its earnings growth rate.
|THRX 113.22||Peers 9.52||THRX 562.92||Peers 8.60|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
THRX is trading at a significant premium to its industry.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
THRX has a sales growth rate that significantly exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV